(12) International Application Status Report

Received at International Bureau: 19 October 2020 (19.10.2020)
Information valid as of: 29 March 2021 (29.03.2021)
Report generated on: 08 August 2023 (08.08.2023)

(10) Publication number:
WO2021/070090

(43) Publication date:
15 April 2021 (15.04.2021)

(26) Publication language:
English (EN)

(21) Application Number:
PCT/IB2020/059430

(22) Filing Date:
07 October 2020 (07.10.2020)

(25) Filing language:
English (EN)

(31) Priority number(s):
62/912,980 (US)

(31) Priority date(s):
09 October 2019 (09.10.2019)

(31) Priority status:
Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
A61P 25/00 (2006.01); ***C07D 401/04*** (2006.01); ***C07D 401/14*** (2006.01); ***C07D 405/14*** (2006.01); ***C07D 413/14*** (2006.01); ***C07D 417/14*** (2006.01); ***A61K 31/454*** (2006.01); **A61K 31/506** (2006.01); ***A61K 31/497*** (2006.01); **A61K 31/53** (2006.01); ***A61K 31/4545*** (2006.01)

(71) Applicant(s):
NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel (CH) *(for all designated states)*

(72) Inventor(s):
CALHOUN, Amy; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
CHEN, Xin; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
GARDINIER, Kevin Matthew; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
HALL, Edward Charles; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
JENDZA, Keith; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
LABBE-GIGUERE, Nancy; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
NEEF, James; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
PALACIOS, Daniel Steven; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
QIAN, Ming; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
SHULTZ, Michael David; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
THOMSON, Christopher G.; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
WANG, Kate Yaping; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)
YANG, Fan; Novartis Institutes for BioMedical Research, Inc. 250 Massachusetts Avenue Cambridge, Massachusetts 02139 (US)

(74) Agent(s):
NOVARTIS AG; Lichtstrasse 35 4056 Basel (CH)

(54) Title (EN): 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS

(54) Title (FR): DÉRIVÉS DE 2-AZASPIRO[3,4] OCTANE UTILISÉS EN TANT QU'AGONISTES DE M4

(57) Abstract:

(EN): Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R^1, R^2, R^3, R^5, and R^7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

(FR): L'invention concerne des composés selon la formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci, dans laquelle R^1, R^2, R^3, R^5 et R^7 sont tels que définis dans la description. L'invention concerne également des compositions pharmaceutiques comprenant un composé de formule (I) ainsi que l'utilisation de tels composés en tant qu'agonistes du récepteur M4.

International search report:
Received at International Bureau: 18 November 2020 (18.11.2020) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:
Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate
Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii))